Celldex Therapeutics
CLDX
184 hedge funds and large institutions have $1.83B invested in Celldex Therapeutics in 2025 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 59 increasing their positions, 57 reducing their positions, and 26 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
24% more capital invested
Capital invested by funds: $1.48B → $1.83B (+$351M)
19% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 26
2% more funds holding
Funds holding: 180 → 184 (+4)
4% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 57
2.42% less ownership
Funds ownership: 108.93% → 106.51% (-2.4%)
53% less call options, than puts
Call options by funds: $3M | Put options by funds: $6.44M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$25.3M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$13.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.2M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$11.7M |
| 5 |
Millennium Management
New York
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.3M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$30.2M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$12.6M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.2M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.1M |
CLDX Hedge Fund Activity: Q3 2025 in Review
184 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2025, worth a combined $1.83B — up 24% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new CLDX positions and 26 closed out — a net gain of 5 holders — while 59 added to existing stakes and 57 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $25.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $33.3M.
- 184 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2025, up from 180 in Q2 2025.
- Funds reported $1.83B of Celldex Therapeutics stock for Q3 2025, up 24% quarter-over-quarter.
- 31 funds opened new Celldex Therapeutics positions in Q3 2025 and 26 closed out, a net change of +5 holders.
- The largest Celldex Therapeutics buyer in Q3 2025 was Point72 Asset Management, an estimated $25.3M added.
- The largest Celldex Therapeutics seller in Q3 2025 was T. Rowe Price Associates, an estimated $33.3M sold.
Based on aggregated 13F filings for Q3 2025.